Interactive tools

Galderma Presents Phase 3 Relfydess Data and Dysport Innovations at TOXINS 2026

Long-Term Real-World Data Show Cutaneous Benefits of Belimumab

Amlitelimab Demonstrates Efficacy With Every-12-Weeks Dosing in AD Trials

National Survey Highlights Unmet Needs and TCS Concerns in Chronic Inflammatory Skin Diseases

Highlighting Upcoming Aesthetic Innovations in 2026

Welcoming a New Year of Progress and Clinical Innovation

The Aesthetic Edge: January 2026

Case-Based Perspectives on Biologic Treatment for Hidradenitis Suppurativa

LEVEL UP Study Shows Benefits of Switching From Dupilumab to Upadacitinib in AD

Atopia Therapeutics Reports Positive Preclinical Data for ATP-R13 as Disease-Modifying Oral AD Therapy